Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01639937 · ClinicalTrials.gov registry record
Myocardial Perfusion and Scarring in Congenital Heart Disease
A clinical trial, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Terminated
- Registry status
- 18
- Enrollment target
NCT01639937 is a clinical trial that was terminated before completion, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 18 participants.
The verdict
NCT01639937 was terminated before completion, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- TERMINATED
- Registry status
- 18 participants
- Enrollment target
Study Summary
Background: \- People with congenital heart disease may develop heart failure earlier that those who do not have the disease. One theory to explain this is that the heart s own blood supply may be different in people with congenital heart disease. Problems with this blood supply can severely damage the heart. This damage can be studied with a heart imaging test called a cardiac magnetic resonance imaging (MRI) scan. Researchers want to use this type of scan to look at the blood supply to the heart in people with congenital heart disease. Objectives: \- To learn more about the blood supply to the heart in people with congenital heart disease. Eligibility: \- Individuals at least 18 years of age who have heart defects caused by congenital heart disease. Design: * Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. * Participants will have a cardiac MRI scan to look at the blood flow to the heart. * Participants will also have a heart stress test to measure heart function during exercise. * Other imaging studies of the heart may be performed to collect more information on heart function.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2012-10-24 |
| Est. Completion | 2019-12-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01639937
The ClinicalTrials.gov registry entry for NCT01639937 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01639937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01639937 about?
NCT01639937 is a clinical study titled "Myocardial Perfusion and Scarring in Congenital Heart Disease". Background: \- People with congenital heart disease may develop heart failure earlier that those who do not have the disease. One theory to explain this is that the heart s own blood supply may be different in people with congenital heart disease. Problems with this blood supply can severely damage...
What is the current status of trial NCT01639937?
This trial is currently terminated. The enrollment target is 18 participants. The study started on 2012-10-24. Estimated completion is 2019-12-12.
Who is sponsoring clinical trial NCT01639937?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.